Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lisa M. Almond"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 3, Pp 386-395 (2024)
Abstract Evaluating the safety of primaquine (PQ) during breastfeeding requires an understanding of its pharmacokinetics (PKs) in breast milk and its exposure in the breastfed infant. Physiologically‐based PK (PBPK) modeling is primed to assess the
Externí odkaz:
https://doaj.org/article/aa9102fcfe9a425088a237c1b9f432c6
Autor:
Nada Abla, Lisa M. Almond, Jennifer J. Bonner, Naomi Richardson, Timothy N. C. Wells, Jörg J. Möhrle
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 7, Pp n/a-n/a (2024)
Abstract The urgent need for safe, efficacious, and accessible drug treatments to treat coronavirus disease 2019 (COVID‐19) prompted a global effort to evaluate drug repurposing opportunities. Pyronaridine and amodiaquine are both components of app
Externí odkaz:
https://doaj.org/article/b1435c1eb5384ac68249a48fb0f8c3e7
Autor:
Nada Abla, Eleanor Howgate, Karen Rowland‐Yeo, Maurice Dickins, Mackenzie C. Bergagnini‐Kolev, Kuan‐Fu Chen, Savannah McFeely, Jennifer J. Bonner, Laura G. A. Santos, Nathalie Gobeau, Howard Burt, Zoe Barter, Hannah M. Jones, David Wesche, Susan A. Charman, Jörg J. Möhrle, Jeremy N. Burrows, Lisa M. Almond
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 9, Pp 1335-1346 (2023)
Abstract As part of a collaboration between Medicines for Malaria Venture (MMV), Certara UK and Monash University, physiologically‐based pharmacokinetic (PBPK) models were developed for 20 antimalarials, using data obtained from standardized in vit
Externí odkaz:
https://doaj.org/article/9ba16da913cf47668851fe83f723f4b5
Autor:
Eunjin Hong, Regina Li, Alan Shi, Lisa M. Almond, Joshua Wang, Amin Z. Khudari, Soumar Haddad, Sarkis Sislyan, Marissa Angelich, Peter S. Chung, Adupa P. Rao, Paul M. Beringer
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 43:291-299
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::314951fb4c28a46424a25ec52bce3c26
https://doi.org/10.1002/phar.2786
https://doi.org/10.1002/phar.2786
Publikováno v:
Clinical pharmacology and therapeutics. 111(6)
Cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, including elexacaftor-tezacaftor-ivacaftor, are primarily eliminated through cytochrome P450 (CYP) 3A-mediated metabolism. This creates a therapeutic challenge to the tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a947c2bcb49cb91b6ab88fc5a38a30ea
https://pubmed.ncbi.nlm.nih.gov/35292968
https://pubmed.ncbi.nlm.nih.gov/35292968
Publikováno v:
Journal of Antimicrobial Chemotherapy (JAC); Oct2005, Vol. 56 Issue 4, p738-744, 7p
Autor:
Lisa M. Almond, Marta Boffito, Patrick G. Hoggard, Stefano Bonora, Riccardo Raiteri, Helen E. Reynolds, Silvia Garazzino, Alessandro Sinicco, Saye H. Khoo, David J. Back, Giovanni Di Perri
Publikováno v:
AIDS Research & Human Retroviruses; 7/01/2004, Vol. 20 Issue 7, p716-722, 7p